# CRISPR gene editing: Materials

Source page: https://www.materialinsights.org/technologies/crispr_gene_editing/tech-materials/

#### Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
 Uses

- [Enz Industrial enzymes](https://www.materialinsights.org/chemicals/enzymes/) criticality low The Cas protein is the cutting enzyme of the system ^[1].
- [Pep Peptides and oligonucleotides](https://www.materialinsights.org/chemicals/peptides_oligos/) criticality low The guide RNA is a short nucleic acid made to order for each target.
- [Rgt Reagents and high-purity lab chemicals](https://www.materialinsights.org/chemicals/lab_reagents/) criticality low Research and production use high-purity laboratory chemicals and growth media.

as of 2026-11-11. No amounts are given: the inputs are small amounts of specialised chemicals, and the dual-use rule keeps production detail out. Criticality is the writer's judgement.

#### Critical materials

The materials whose supply could hold it back

- No raw material is likely to hold gene editing back: enzymes and short RNAs are made in small amounts.
- The constraints are policy ones: medicines need approval by regulators such as the MHRA and FDA ^[3, 4], and WHO's 2021 recommendations call for registries of human genome editing research and a way to report concerns ^[5].
- Editing embryos so that changes pass to children carries risks that WHO singles out ^[5].

as of 2026-11-11

#### Sources

1. [A Tool for Genome Editing: Scientific Background on the Nobel Prize in Chemistry 2020](https://www.kva.se/app/uploads/2020/10/scibackkeen20.pdf) Royal Swedish Academy of Sciences, 2020
2. [FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease) US Food and Drug Administration, 2023
3. [MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia](https://www.gov.uk/government/news/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia) Medicines and Healthcare products Regulatory Agency (GOV.UK), 2023
4. [WHO issues new recommendations on human genome editing for the advancement of public health](https://www.who.int/news/item/12-07-2021-who-issues-new-recommendations-on-human-genome-editing-for-the-advancement-of-public-health) World Health Organization, 2021

## Other sections

- [Summary](https://www.materialinsights.org/technologies/crispr_gene_editing/index.md)
- [Overview](https://www.materialinsights.org/technologies/crispr_gene_editing/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/crispr_gene_editing/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/crispr_gene_editing/tech-evolution/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/crispr_gene_editing/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/crispr_gene_editing/tech-industries/index.md)
